Patients with Kallmann syndrome or severe CHH have been shown to respond more poorly to gonadotropin or GnRH therapy in adolescence than those with less severe GnRH deficiency in utero, with smaller posttreatment testicular volumes (159) and lower total sperm counts by the end of a treatment cycle (139, 160-164). This evidence concerns the gene GNRH1 and Kallmann syndrome.